Authors: Jade Parker, Editor
Today at our booth
Today marked the first day of ASCO 2018, here in Chicago. The conference has already been packed with new advancements and data from studies that could significantly impact clinical practice within oncology. Take a look at some of our highlights below, and tell us your thoughts in the comments below.
Remember you can find us at booth #4040, or follow our Twitter updates @OncologyCentral.
Why you should visit booth #4040 tomorrow
Picture of the Day
We have arrived in Chicago!
Tomorrow’s key talk to attend
LOXO-292 data (abstract 102) – Saturday 2 June, 8:36–8:48 in Hall D1
Age-related concerns in cancer patients: geriatric assessment improves doctor-patient communication
Researchers at the University of Rochester (NY, USA) have demonstrated that the use of geriatric assessment in routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns as well as patient satisfaction with the communication.
Abiraterone for advanced prostate cancer may be more effective for black men than white men
A prospective clinical trial, involving 100 men with metastatic castration-resistant prostate cancer, has demonstrated that black men experience a greater and longer lasting response to the hormone treatment abiraterone (Zytiga®) compared with white men. Furthermore, black men were more likely to have a decline in PSA and had a 5-month longer median time to PSA worsening than white men (16.6 vs. 11.5 months).
Study reveals gender disparities in head and neck cancer treatment and outcomes
An analysis from a California hospital system has demonstrated that women with head and neck cancer are less likely to receive intensive chemotherapy and radiation compared to men. Furthermore, the ratio of cancer to non-cancer mortality was 1.92 times higher for women than for men.
Prostate cancer survival in black men following chemotherapy may be as good, or better, as in white men
Analysis of data from more than 8000 men with advanced prostate cancer who received chemotherapy suggests survival chances for black men are at least as good as those for white men when provided with equal treatment.
Best of social media #ASCO18
Oncology innovation is high. Over the past 5 years, 78 #cancer drugs have been launched covering 24 different #tumor types with some for the treatment of multiple tumor types. Learn more >> https://t.co/S0MhgeQWUa#ASCO18 pic.twitter.com/heVmu07rMw
— Murray Aitken (@Murray_Aitken) May 29, 2018
#ASCO18 is upon us! Here are our now classic ground rules about asking that question after a talk. @ASCO @JGO_ASCO if you know the author, let me know, I’ve never been able to give due credit. If you’re doctor Vogl from NY you’re exempt (are you on twitter?) pic.twitter.com/hDXU9WZoKo
— gilberto lopes (@GlopesMd) May 31, 2018
Save this pic! The std hashtags from @JAMAOnc article by @subatomicdoc et al to share or catch up on missed disease-specific content during many great competing sessions at @ASCO Annual Mtg. #ASCO18 pic.twitter.com/ctPHmgItaM
— Tatiana Prowell, MD (@tmprowell) May 31, 2018
Not sure there is any better pre-ASCO pick-me-up than giving a patient good scan results.
Not sure there is any more timely pre-ASCO reality check than helping a patient with side effects.
Here’s to more efficacy, less toxicity, and always patient-centric care.
— Mark Lewis (@marklewismd) May 30, 2018